Latin America has a high prevalence of Helicobacter pylori infection and associated diseases, including gastric cancer. Antibiotic therapy can eradicate the bacterial infection and decrease associated morbidity and mortality. To tailor recommendations for optimal treatments, we summarized published literature and calculated region-and country-specifi c prevalences of antibiotic resistance.
INTRODUCTION
Chronic Helicobacter pylori infection is causally related to serious benign and malignant upper gastrointestinal diseases, including peptic ulcer, gastric mucosa-associated lymphoid tissue lymphoma, and gastric cancer ( 1 ). Conversely, eradication of H. pylori is associated with ulcer healing ( 2 ) , regression of mucosa-associated associated lymphoid tissue lymphoma ( 3 ) , and decreased cancer risk ( 4 ) . Successful treatment for H. pylori infection requires multidrug regimens, which are frequently based on clarithromycin as the central component. Eradication rates vary with level of antibiotic resistance (5, 6) , and, according to one guideline ( 7 ) , the use of clarithromycin without susceptibility testing is not recommended in populations with more than 15 -20 % prevalence of resistant isolates.
Many Latin American countries have a high burden of H. pylori infection ( 8, 9 ) and associated diseases, particularly gastric cancer ( 10 ) . Th is geographic region also has multiple avenues of unfettered access to antibiotics, including selfmedication, unnecessary prescriptions, and lax regulation of sales ( 11 ) . In order to guide treatment choice and tailor eradication 
METHODS
Review methods and reporting were performed according to the PRISMA guidelines ( 12 ) .
Search strategy and selection criteria
Th e literature databases PubMed (United States National Library of Medicine, Bethesda, MD), LILACS (Latin America and the Caribbean Literature on Health Sciences; http://lilacs.bvsalud. org/en ), and SciELO (Scientifi c Electronic Library Online; http:// www.scielo.org ) were searched for observational studies evaluating H. pylori antibiotic resistance in the 20 countries comprising Latin America, as defi ned by the United Nations Educational Scientifi c and Cultural Organization ( 13 ) , published in any language up to 31 October 2013.
To identify studies in PubMed, the following search strategy was used: Helicobacter pylori, and antimicrobial resistance or antibiotic resistance or " Drug Resistance, Microbial " [Mesh] Two investigators (C.A.C. and T.H.-G.) independently reviewed titles and abstracts for selection of potentially relevant articles; any disagreement was resolved by consulting a third reviewer (A.G.). Full-text articles were retrieved for potential inclusion if data on resistance to at least one antibiotic were reported. Citations of retrieved articles were reviewed for studies that may have been missed or were absent from our database queries.
Th e following information was abstracted from each selected article: fi rst author, year of publication, study location (country), year of sample collection, participant age (range or mean), prior antibiotic treatment for H. pylori , number of patients, histologic diagnoses, number of samples (gastric biopsies or H. pylori isolates), prevalence of antibiotic resistance, and method of resistance assessment (agar dilution, E-test, disk diff usion, or detection of point mutations by polymerase chain reaction). To ensure comparability across studies, we contacted the corresponding authors to enquire about missing data on prior antibiotic treatment for H. pylori . In all, 20 of the 21 authors contacted provided unpublished information. We also obtained additional unpublished data for 11 studies on year of sample collection and potentially overlapping sample sets.
In order to assess quality (risk of bias) of the included studies, we evaluated the following characteristics: (1) representativeness of the patients; (2) consecutive or random selection for inclusion; (3) adequacy of description of patient characteristics (e.g., demographics, year of sample collection, histologic diagnoses, and so on); (4) accounting of study fl ow (e.g., percentage of not consenting, percentage of failed cultures, percentage of inconclusive results, and so on); and (5) validity of testing methodology. Each domain was coded individually as " + " (i.e., low risk of bias), " − " (i.e., high risk of bias), or " ? " (i.e., unclear).
Statistical analysis
All of our analyses were restricted to adults. We used randomeff ects models ( 14 ) to summarize double arcsine -transformed ( 15 ) prevalences of primary resistance to antibiotics, for which more than fi ve articles were identifi ed. Summary prevalences and corresponding 95 % confi dence intervals (CIs) were calculated by back-transformation. Study-specifi c results are presented for antibiotics reported in two to four articles, but antibiotics reported in a single study were not summarized. Given their similar antimicrobial activity, data on levofl oxacin and ciprofl oxacin resistance were combined. Between-study heterogeneity was assessed for statistical signifi cance using the Q test and quantifi ed with the I 2 statistic as low ( < 25 % ), moderate (25 -50 % ), or high ( > 50 % ) ( 16 ) . If moderate or high heterogeneity was identifi ed for a given antibiotic, meta-regression models were used to examine the extent to which country, year of sample collection (1988 -1995, 1996 -2000, 2001 -2005, or 2006 -2011) , or test method may be explanatory. For one study that reported antibiotic resistance by anatomic subsite of sample collection (i.e., antrum or corpus), we used a random-eff ects model to estimate the overall prevalence. For 15 articles that did not state when samples were collected, year of collection was imputed as being 4 years prior to publication on the basis of the median diff erence between sample collection and publication year for the remaining articles. Sensitivity analyses were performed by including studies that evaluated secondary resistance (i.e., with prior antibiotic treatment for H. pylori ) as well as those that did not specify prior antibiotic exposure. For each of the evaluated antibiotics, publication bias was investigated by visual inspection of Begg ' s funnel plots ( 17 ) and was formally tested using Egger ' s regression asymmetry method ( 18 ) . Meta-analyses were performed with Stata version 11 (StataCorp, College Station, TX, USA) using a combination of published macros ( 19 ) . A P value of less than 0.05 was considered statistically signifi cant for all tests, except the heterogeneity and Egger tests for which a P value less than 0.10 was considered signifi cant. All statistical tests were two-sided.
RESULTS

Literature search and description of studies
Th e literature searches identifi ed a total of 201 articles: 106 from PubMed, 49 from LILACS, and 46 from SciELO ( Figure 1 ). Aft er excluding 146 irrelevant or duplicate publications, 55 full-text articles were retrieved for further evaluation; 9 additional publications were identifi ed from citations of these articles. Five articles were excluded because the respective authors had other publications involving the same antibiotic in larger, but overlapping, samples. Th us, a total of 59 articles (38 written Figure S1 ) . Th e overall summary prevalence was 12 % , with high between-study heterogeneity ( Table 2 ). Peru (50 % , n = 1) reported the highest prevalence, whereas Paraguay (2 % , n = 1) reported the lowest. Prevalences did not diff er signifi cantly by period of collection ( Table 2 ) . Furthermore, prevalence estimates did not vary signifi cantly by test method ( P = 0.9): the estimates were 13 % ( n = 16) for agar dilution, 12 % ( n = 14) for E-test, 14 % ( n = 4) for disk diff usion, and 8 % ( n = 1) for PCR. Th e summary prevalence including studies evaluating secondary ( n = 7) resistance was 12 % (95 % CI, 9 -16 % ; n = 42).
Metronidazole . Prevalences of primary resistance to metronidazole were reported in 34 studies. Study-specifi c prevalences ranged from 12.5 % to 95 % ( Supplementary Figure S2 ) . Th e summary prevalence was 53 % with high heterogeneity among studies ( Table 2 ) . Th e highest resistance was reported in Colombia (83 % , n = 4; Table 3 ), whereas the lowest was reported in Argentina (30 % , n = 3). Prevalences did not diff er signifi cantly by period of collection ( Table 2 ). Furthermore, prevalence estimates did not vary signifi cantly by test method ( P = 0.3): the estimates were 44 % for agar dilution ( n = 13), 57 % ( n = 16) for E-test, 62 % ( n = 3) for disk diff usion, and 59 % ( n = 2) for PCR. Th e summary prevalence including studies evaluating secondary ( n = 5) or unspecifi ed ( n = 1) resistance was 56 % (95 % CI, 49 -63 % ; n = 40).
Amoxicillin . Twenty-eight studies examined primary resistance to amoxicillin. Study-specifi c prevalences ranged from 0 % to 39 % . Th e summary prevalence was 4 % , with high heterogeneity among the studies ( Table 2 ) . Th e highest resistance was reported in Brazil (15 % , n = 5; Table 3 ). Prevalence did not diff er signifi cantly by period of collection ( Table 2 ). Furthermore, prevalence estimates did not vary signifi cantly by test method ( P = 0.5): the estimates were 6 % ( n = 14) for agar dilution, 3 % ( n = 12) for E-test, and 3 % ( n = 2) for disk diff usion. Th e summary prevalence including studies evaluating secondary ( n = 5) or unspecifi ed ( n = 1) resistance was 4 % (95 % CI, 2 -8 % ; n = 34).
Tetracycline . Primary resistance to tetracycline was evaluated in 20 studies. Study-specifi c prevalences ranged from 0 % to 86 % . Th e summary prevalence was 6 % with high between-study heterogeneity ( Table 2 ) . Th e highest resistance was reported in Colombia (86 % , n = 1; Table 3 ). Prevalence did not diff er signifi cantly by period of collection ( Table 2 ). However, prevalence estimates varied signifi cantly by test method ( P = 0.0002): the estimates were 6 % ( n = 9) for agar dilution, 1 % ( n = 7) for E-test, 86 % ( n = 1) for disk diff usion, and 10 % ( n = 3) for PCR. Th e summary prevalence including studies evaluating secondary ( n = 3) or unspecifi ed ( n = 1) resistance was 7 % (95 % CI, 2 -14 % ; n = 24).
Furazolidone . Primary resistance to furazolidone was studied only in Brazil ( n = 6), with study-specifi c prevalences ranging from 0 % to 14 % . Th e summary prevalence was 3 % with high heterogeneity across studies ( Table 2 ). Prevalences did not diff er signifi cantly by period of collection ( Table 2 ). All studies used agar dilution to assess resistance. 2011 for assessing resistance to clarithromycin, metronidazole, amoxicillin, tetracycline, furazolidone, levofl oxacin, and / or ciprofl oxacin were included in this analysis ( Supplementary Table  online) . Other antibiotics that were reported in single studies and therefore were not summarized included azithromycin, trovafl oxacin, ampicillin, and doxycycline.
Fift y-six studies reported on adults, two only on children and one had both population groups. A total of 14 studies were conducted in Brazil, 11 in Colombia, 9 in Mexico, 5 in Chile, 5 in Argentina, 3 
Assessment of study quality
In general, the reviewed studies included a representative spectrum of patients and used valid methods to assess resistance ( Table 1 ) . Th ere were some defi ciencies with regard to the reporting of sampling strategy and patient characteristics. Nevertheless, based on the information for sample collection period, it seems likely that most studies used consecutive or random selection.
Summary estimates of resistance in adults
Clarithromycin . Th irty-fi ve studies examined primary resistance to clarithromycin. Study-specifi c prevalences ranged from 0 % Table ) with study-specifi c prevalences ranging from 4 % to 37 % . Th e summary prevalence was 15 % with high heterogeneity across studies ( Table 2 ). Four studies used E-test to assess resistance (11 % ; 95 % CI, 4 -19 % ). Th e summary prevalence including 
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broad spectrum of antibacterial activity, resistance to this agent may evolve rapidly. Th e overall prevalence of fl uoroquinolone resistance in Latin America is higher than the overall levofl oxacin resistance rates reported for Europe (14.1 % ) ( 25 ) and Asia (11.6 % ) ( 26 ) . Urinary tract Escherichia coli isolates in Latin America also have a high prevalence of this resistance ( 29 ) . Levofl oxacin should not be used for fi rst-line therapy of H. pylori infections. Th is antibiotic should only be considered for patients with clarithromycin-resistant isolates and for retreatment of patients who failed fi rst-line clarithromycin-based therapies ( 7 ). Regarding metronidazole, our meta-analysis found that resistance in Latin American populations was high and stable over the study period without remarkable trends within individual countries. Although concerns have been raised regarding lack of reproducibility of metronidazole testing for individual diagnosis ( 30, 31 ) , the trend of low, medium, or high prevalences provides useful information at a population level ( 32 ) . In contrast to clarithromycin, metronidazole resistance is not of great clinical relevance, as it can be overcome by increasing the length of treatment or by adding bismuth to the regimen ( 33 ) .
Th e relatively low overall prevalence of amoxicillin resistance in Latin America is similar to that of other regions ( 25 ) . Th us, inclusion of this antibiotic in empiric eradication regimens is still appropriate worldwide.
In some areas, local variation in H. pylori antibiotic resistance is associated with the use of the same antibiotic in the general population ( 25, 34 ) . On the basis of retail sales data, total per capita consumption of antibiotics in Latin America was found to have increased by nearly 10 % between 1997 and 2007 ( 35 ) . Th e 10-year sales trends for macrolide, lincosamide, and streptogramin antibiotics showed large increases in Peru, Brazil, and Argentina but relatively little change, or even decreases, in Uruguay, Mexico, and Colombia. In 2007, the countries with highest per capita consumption of macrolides (including clarithromycin) and related antibiotics were Venezuela, Argentina, and Chile. Fluoroquinolone use, including levofl oxacin, signifi cantly increased throughout the region, with the highest consumption for 2007 recorded in the same three countries. Th e patterns in these retail data do not seem to correlate with the variation in prevalence of antimicrobial resistance, but further eff orts should be directed to better monitor local and national antibiotic consumption.
Between-study heterogeneity was high in all meta-analyses and could not be explained by variation in country, period of sample collection, and test method. In previous studies, both patient (e.g., sex ( 36 ) , age (25) , and diagnosis ( 37 )) and bacterial (e.g., cagA positivity ( 38, 39 ) ) characteristics have been associated with antibiotic resistance, and could therefore infl uence heterogeneity. Unfortunately, we did not have detailed data to assess such variation.
Th e majority of studies evaluated resistance by either agar dilution or E-test, which are both considered to be highly accurate and equivalently valid testing methodologies ( 40 ) . Although in general we found no variation by testing method, studies using disk diff usion tended to provide higher resistance estimates. Nevertheless, these fi ndings should be interpreted cautiously, as prevalence was 8 % with high heterogeneity among studies ( Table 2 ) . Th e highest resistance was reported in Mexico (13 % , n = 4; Table 3 ), whereas the lowest was reported in Paraguay (2 % , n = 1). Prevalences did not diff er signifi cantly by period of collection ( Table 2 ) . Th e summary prevalence including studies evaluating secondary resistance ( n = 3) was 7 % (95 % CI, 4 -10; n = 13).
Pediatric studies
As compared with adults, higher prevalences were observed in the three studies in children ( Supplementary Table ) for resistance to clarithromycin (ranging from 19 % to 27 % ) and dual resistance to clarithromycin and metronidazole (18 % ), whereas lower prevalences were reported for metronidazole (ranging from 13 % to 78 % ), tetracycline (0 % ), and furazolidone (0 % ). No pediatric data were available for resistance to fl uoroquinolones.
Publication bias
For studies in adults, the P values for Egger ' s test were equal or greater than 0.10 for all antibiotics ( Table 2 ). Funnel plots confi rmed symmetric distributions.
DISCUSSION
Antibiotic resistance patterns of H. pylori may predict the efficacy of current antibiotic regimens and may suggest new treatment strategies. Our study represents the fi rst systematic eff ort to review and synthesize available data in Latin America. Our analysis indicates that H. pylori resistance to fi rst-line antibiotics is high in some countries, which may contribute to high rates of treatment failure in this region.
Th ree-drug regimens including a proton pump inhibitor (PPI), clarithromycin, and either metronidazole or amoxicillin have been widely recommended as a fi rst choice for H. pylori eradication with success rates of around 80 % ( 7, 20 ) . However , this approach has decreased the effi cacy of antibiotics in individuals with antibiotic-resistant strains ( 5, 21, 22 ) . In the presence of clarithromycin or metronidazole resistance, the success rate of a PPIclarithromycin -metronidazole regimen is signifi cantly reduced by 35 % and 18 % , respectively. Th e decrease in success is 66 % in case of clarithromycin resistance if the treatment contains PPIclarithro mycin -amoxicillin ( 5, 23 ) . Alternative fi rst-line regimens include bismuth-containing quadruple, sequential, concomitant quadruple, and hybrid therapies ( 24 ) .
According to the fourth edition of the European Maastricht Consensus ( 7 ), PPI clarithromycin -containing triple therapy without prior susceptibility testing should be abandoned in a given region when the local clarithromycin resistance rate is more than 15 -20 % . Levels within or above this range have already been reported in some European and Asian countries ( 25 -28 ) . Similarly, although the overall prevalence in Latin America (13 % ) was below this threshold, our meta-analysis suggests that empirical use of clarithromycin may not be appropriate in Peru, and perhaps in Colombia.
Levofl oxacin is frequently substituted for clarithromycin in second-line treatment regimens for H. pylori infections. Given its REVIEW Camargo et al. they were not based on studies directly comparing the techniques on the same H. pylori isolates.
Th e data we summarized mainly represent convenience samples of adults from 12 of the 20 Latin American countries. Most patients were recruited in specialized medical centers, with uncertain relevance to the appropriate target population for H. pylori eradication in Latin America. Also, there were only three reports regarding bacterial isolates from children. All the reviewed studies were at least moderate in quality with low risk of contributing bias to our systematic analysis. We found no evidence of publication bias.
Apart from antibiotic resistance, other determinants of eradication success include smoking, medication adherence, and host genetic variation. Smokers have a twofold increased risk of eradication failure ( 41 ) . Poor adherence with the medication regimen is inversely associated with the probability of therapeutic success ( 42, 43 ) . Carriage of alleles encoding active cytochrome P450 2C19 isoenzymes is associated with increased PPI metabolism and diminished pharmacologic eff ect; these genotypes are common in Latin American populations ( 44, 45 ) . Success rates could be improved by strategies to reduce smoking and enhance adherence (e.g., counseling regarding medication side eff ects and risk of antibiotic resistance with treatment failure).
Surveillance systems for H. pylori antimicrobial resistance have proven useful for informing practitioners about empirical choices for treatment ( 25, 36 ) . Organized surveillance eff orts in Latin American countries therefore warrant serious consideration. Th ese systems could be set up using already established networks currently monitoring antibiotic resistance to other bacteria, such as the World Health Organization Collaborating Centre for Surveillance of Antimicrobial Resistance (WHONET), the Red Latinoamericana de Vigilancia de la Resistencia a los Antimicrobianos (ReLAVRA), the Alliance for the Prudent Use of Antibiotics (APUA), and the SENTRY antimicrobial surveillance program.
In conclusion, our meta-analysis demonstrated high H. pylori resistance to fi rst-line antibiotics in Latin American countries. Th is fi nding stresses the need for appropriate surveillance programs, improved institutional and governmental antimicrobial regulations, and increased public awareness and knowledge. Implementation of safe and eff ective eradication regimens can help alleviate the burden of H. pylori -related diseases, and in particular, to reduce the high incidence of gastric cancer in this region.
